Render Target: SSR
Render Timestamp: 2024-11-14T23:01:59.444Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:57:34.716
Product last modified at: 2024-11-08T14:00:11.130Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

PML (E6S9L) Rabbit mAb #69789

Filter:
  • IHC
  • IF

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 48-200
    Source/Isotype Rabbit IgG
    Application Key:
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Immunohistochemistry (Paraffin) 1:500 - 1:2000
    Immunofluorescence (Immunocytochemistry) 1:500

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    PML (E6S9L) Rabbit mAb recognizes endogenous levels of total PML protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human PML protein.

    Background

    Promyelocytic leukemia protein (PML) functions via its association with PML bodies in the nucleus (1). PML bodies are dynamic protein aggregates that are interspersed between chromatin in the nuclei of most mammalian cells. The PML protein acts as a scaffold in PML bodies to recruit other proteins, a process regulated by post-translational modifications, such as sumoylation. PML bodies function to regulate a large number of cellular processes, such as tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense (1). The chromosomal translocation t(15;17)(q21;q21) involving the fusion of PML and RARalpha is found in acute promyelocytic leukemia (APL), while a second translocation t(9;15)(p13;q24) involving the fusion of PML and PAX5 was found in acute lymphoblastic leukemia (ALL) (2-6). In addition, PML is frequently inactivated or downregulated in cancer.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.